A Competing Risks Model with Time Varying Covariates for Estimation of Breast Cancer Risks in BRCA1 Families

Mammographic screening and prophylactic surgery can potentially reduce breast cancer risks among mutation carriers of BRCA families. The evaluation of these interventions is usually complicated by the fact that their effects may change over time and by the presence of competing risks. We propose a competing risks model that accounts for time-varying interventions and provide cause-specific penetrance estimates for breast and ovarian cancers in BRCA1 families. A shared frailty model is specified to account for familial residual dependence with an ascertainment correction through affected probands, which accounts for competing risks and time-varying covariates (TVCs). Via simulation studies we demonstrate the good performances of our proposed approach in terms of bias and precision of the estimators of model parameters and cause-specific penetrances over different levels of familial correlations. We apply our new approach to 498 BRCA1 mutation carrier families recruited through the Breast Cancer Family Registry and illustrate the importance of our approach accounted for both competing risks and TVCs when estimating cause-specific penetrance of breast cancer.

[1]  Jacques Simard,et al.  Sequence kernel association test for survival outcomes in the presence of a non-susceptible fraction. , 2020, Biostatistics.

[2]  H. Jacqmin-Gadda,et al.  Joint nested frailty models for clustered recurrent and terminal events: An application to colonoscopy screening visits and colorectal cancer risks in Lynch Syndrome families , 2020, Statistical methods in medical research.

[3]  W. Chung,et al.  Risk-Reducing Oophorectomy and Breast Cancer Risk Across the Spectrum of Familial Risk , 2018, Journal of the National Cancer Institute.

[4]  J. Horrocks,et al.  Exponential decay for binary time‐varying covariates in Cox models , 2018, Statistics in medicine.

[5]  W. Chung,et al.  Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers , 2017, JAMA.

[6]  W. Chung,et al.  Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers , 2017, Journal of the National Cancer Institute.

[7]  Aung Ko Win,et al.  Modeling of successive cancer risks in Lynch syndrome families in the presence of competing risks using copulas , 2017, Biometrics.

[8]  A. Whittemore,et al.  Cohort Profile: The Breast Cancer Prospective Family Study Cohort (ProF-SC) , 2015, International journal of epidemiology.

[9]  A. Green,et al.  Gene analysis techniques and susceptibility gene discovery in non-BRCA1/BRCA2 familial breast cancer. , 2015, Surgical oncology.

[10]  M. Pollán,et al.  Cumulative risk of second primary contralateral breast cancer in BRCA1/BRCA2 mutation carriers with a first breast cancer: A systematic review and meta-analysis. , 2014, Breast.

[11]  G. Parmigiani,et al.  Recent BRCAPRO Upgrades Significantly Improve Calibration , 2014, Cancer Epidemiology, Biomarkers & Prevention.

[12]  G. Parmigiani,et al.  Calibrated predictions for multivariate competing risks models , 2014, Lifetime data analysis.

[13]  D. Easton,et al.  BOADICEA breast cancer risk prediction model: updates to cancer incidences, tumour pathology and web interface , 2013, British Journal of Cancer.

[14]  Malka Gorfine,et al.  Frailty‐Based Competing Risks Model for Multivariate Survival Data , 2011, Biometrics.

[15]  A. Wienke Frailty Models in Survival Analysis , 2010 .

[16]  G. Feldman,et al.  Hereditary breast and ovarian cancer due to mutations in BRCA1 and BRCA2 , 2010, Genetics in Medicine.

[17]  Per Kragh Andersen,et al.  Competing Risks and Time‐Dependent Covariates , 2009, Biometrical journal. Biometrische Zeitschrift.

[18]  L. Briollais,et al.  Estimating Disease Risk Associated with Mutated Genes in Family-Based Designs , 2008, Human Heredity.

[19]  Giovanni Parmigiani,et al.  Meta-analysis of BRCA1 and BRCA2 penetrance. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  Norman Boyd,et al.  The Breast Cancer Family Registry: an infrastructure for cooperative multinational, interdisciplinary and translational studies of the genetic epidemiology of breast cancer , 2004, Breast Cancer Research.

[21]  Stephen W Duffy,et al.  A breast cancer prediction model incorporating familial and personal risk factors , 2004, Hereditary Cancer in Clinical Practice.

[22]  L. Cannon-Albright,et al.  Risk modifiers in carriers of brca1 mutations , 1995, International journal of cancer.

[23]  N Risch,et al.  Autosomal dominant inheritance of early‐onset breast cancer. Implications for risk prediction , 1994, Cancer.

[24]  D. Cox,et al.  Analysis of Survival Data. , 1985 .

[25]  J. Kalbfleisch,et al.  The Statistical Analysis of Failure Time Data , 1980 .

[26]  V T Farewell,et al.  The analysis of failure times in the presence of competing risks. , 1978, Biometrics.

[27]  Practice Bulletin No 182: Hereditary Breast and Ovarian Cancer Syndrome. , 2017, Obstetrics and gynecology.

[28]  A. Yashin,et al.  Genetic analysis of durations: Correlated frailty model applied to survival of Danish twins , 1995, Genetic epidemiology.